Ronit Satchi-Fainaro | Pharmacology | Outstanding Scientist Award

Posted on by ScienceFather

Prof Dr. Ronit Satchi-Fainaro | Pharmacology | Outstanding Scientist Award

 Cancer Biology Research Center at Tel Aviv University, Israel

Ronit Satchi-Fainaro is a prominent figure in cancer research, currently serving as a Full Professor in the Department of Physiology and Pharmacology at Tel Aviv University and Director of the Cancer Biology Research Center. With a Ph.D. in polymer chemistry and extensive postdoctoral training at renowned institutions, her research focuses on cancer biology, tumor dormancy, and the development of targeted nanomedicines. Satchi-Fainaro has pioneered multi-modality polymer therapeutics that combine anti-angiogenic agents with chemotherapeutics, significantly advancing the field of cancer treatment. Her impressive publication record includes groundbreaking articles in Nature Medicine and Cancer Cell, and she has filed multiple patents for her innovative findings. Additionally, she has received numerous accolades for her contributions to science, including the Humboldt Foundation Bessel Research Prize. Satchi-Fainaro’s leadership in interdisciplinary research and commitment to translating scientific discoveries into clinical applications make her a leading voice in modern cancer therapeutics.

Professional Profile

Education

Ronit Satchi-Fainaro has an impressive educational background that laid the foundation for her distinguished career in pharmacology and cancer research. She earned her Bachelor of Pharmacy (B.Pharm.) degree in Pharmacology from The Hebrew University, Faculty of Medicine, School of Pharmacy, in June 1995. Following her undergraduate studies, she completed an internship in Industrial Pharmacy at Perio Products Ltd. in Jerusalem in March 1996. Satchi-Fainaro then pursued her Ph.D. at the University of London, specializing in polymer chemistry, biochemistry, and cancer nanomedicine. Her doctoral research, titled “PDEPT: Polymer Directed Enzyme Prodrug Therapy,” was completed in November 1999 under the supervision of Prof. Ruth Duncan. Subsequently, she expanded her expertise through postdoctoral fellowships at Tel Aviv University and Harvard Medical School, focusing on tumor biology, molecular biology, and protein delivery, further solidifying her status as a leader in the field of cancer research and nanomedicine.

 

Professional Experience

Ronit Satchi-Fainaro is a distinguished Full Professor in the Department of Physiology and Pharmacology at Tel Aviv University and serves as the Director of the Cancer Biology Research Center. With over 15 years of leadership at the university, she has spearheaded a multidisciplinary research group focused on innovative cancer therapies. Satchi-Fainaro’s expertise encompasses polymer chemistry, biochemistry, and nanomedicine, leading to the development of targeted polymer therapeutics and nano-vaccines. She has collaborated with prominent institutions, including Harvard Medical School, where she contributed to significant advances in tumor biology and angiogenesis. Her entrepreneurial spirit is evident through her co-founding of biotech companies, such as ImmuNovation, Ltd., and her active role on various scientific advisory boards. Satchi-Fainaro has garnered numerous accolades, including the Humboldt Foundation Bessel Research Prize, reflecting her substantial impact in cancer research and drug delivery systems. Her work continues to push the boundaries of personalized medicine and cancer therapeutics

Research Interests

Ronit Satchi-Fainaro’s research interests lie at the intersection of cancer biology, pharmacology, and nanomedicine. She focuses on understanding the mechanisms underlying cancer dormancy and the tumor-host interactions that facilitate metastasis. Her innovative work involves developing targeted nanomedicines that integrate anti-stromal agents with chemotherapeutics to enhance treatment efficacy while reducing toxicity. Satchi-Fainaro’s laboratory employs advanced techniques such as molecular imaging, 3D bioprinted cancer models, and personalized theranostics to investigate tumor biology and angiogenesis. She aims to identify molecular signatures that predict tumor behavior and survivorship, driving the rational design of novel therapeutic approaches. Additionally, her interdisciplinary approach combines elements of biology, chemistry, engineering, and material sciences, facilitating the development of highly selective drug delivery systems. Through her pioneering research, Satchi-Fainaro aspires to contribute to more effective cancer therapies and improve patient outcomes in the fight against cancer.

Ronit Satchi-Fainaro has received numerous prestigious awards and honors throughout her distinguished career, reflecting her significant contributions to cancer research and nanomedicine. Notable accolades include the British Council Chevening Award, the Nagai Foundation Graduate Student Award, and the Fulbright Scholarship. She was recognized as a “Person of the Year” in Medicine by Forbes Israel and included in various influential lists, such as the “50 Most Influential Women” and “40 Under 40” by prominent Israeli journals. In addition, she has received the ERC Advanced Grant, the 3D Printing Industry Award for Medical Application of the Year, and the Bessel Research Prize from the Humboldt Foundation. Her work has garnered multiple research prizes for exceptional publications at Tel Aviv University and recognition as a Fellow of the American Institute of Medical and Biological Engineers (AIMBE). These accolades highlight her impactful research and leadership in advancing innovative cancer therapies.

 

Conclusion

Ronit Satchi-Fainaro is a distinguished leader in cancer research, whose innovative work in nanomedicine has significantly advanced the understanding and treatment of cancer. With a robust academic background and over 15 years at Tel Aviv University, she has successfully led multidisciplinary research initiatives that tackle complex questions in tumor biology and drug delivery. Her pioneering development of multi-modality targeted nanomedicines has not only garnered numerous patents but also positioned her at the forefront of translational research. Satchi-Fainaro’s impressive publication record in high-impact journals, coupled with her numerous accolades—including the Humboldt Foundation Bessel Research Prize—underscores her contributions to science. As the Director of the Cancer Biology Research Center, she exemplifies a commitment to fostering collaboration and mentorship in the scientific community. Overall, her accomplishments and dedication to improving cancer therapies make her a highly deserving candidate for the Research for Outstanding Scientist Award.

 

Publication top noted
  • Title: interFLOW: maximum flow framework for the identification of factors mediating the signaling convergence of multiple receptors
    Authors: Sheinin, R., Salomon, K., Yeini, E., Sharan, R., Madi, A.
    Year: 2024
    Citations: 0
  • Title: Polyester nanoparticles delivering chemotherapeutics: Learning from the past and looking to the future to enhance their clinical impact in tumor therapy
    Authors: Longobardi, G., Moore, T.L., Conte, C., Satchi-Fainaro, R., Quaglia, F.
    Year: 2024
    Citations: 0
  • Title: Multifunctional Nanovaccine Sensitizes Breast Cancer to Immune Checkpoint Therapy
    Authors: Peres, C., Matos, A.I., Carreira, B., Satchi-Fainaro, R., Florindo, H.F.
    Year: 2024
    Citations: 2
  • Title: Combining TIGIT Blockade with MDSC Inhibition Hinders Breast Cancer Bone Metastasis by Activating Antitumor Immunity
    Authors: Monteran, L., Ershaid, N., Scharff, Y., Zhang, X.H.-F., Erez, N.
    Year: 2024
    Citations: 3
  • Title: The role of CCL2/CCR2 axis in cancer and inflammation: The next frontier in nanomedicine
    Authors: Pozzi, S., Satchi-Fainaro, R.
    Year: 2024
    Citations: 3
  • Title: Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker
    Authors: Liubomirski, Y., Tiram, G., Scomparin, A., Shabat, D., Satchi-Fainaro, R.
    Year: 2024
    Citations: 3
  • Title: Intranasal Multiepitope PD-L1-siRNA-Based Nanovaccine: The Next-Gen COVID-19 Immunotherapy
    Authors: Acúrcio, R.C., Kleiner, R., Vaskovich-Koubi, D., Florindo, H.F., Satchi-Fainaro, R.
    Year: 2024
    Citations: 0
  • Title: Polyoxazoline-Based Nanovaccine Synergizes with Tumor-Associated Macrophage Targeting and Anti-PD-1 Immunotherapy against Solid Tumors
    Authors: Matos, A.I., Peres, C., Carreira, B., Satchi-Fainaro, R., Florindo, H.F.
    Year: 2023
    Citations: 6
  • Title: Deoxyhypusine hydroxylase: A novel therapeutic target differentially expressed in short-term vs long-term survivors of glioblastoma
    Authors: Ofek, P., Yeini, E., Arad, G., Geiger, T., Satchi-Fainaro, R.
    Year: 2023
    Citations: 4
  • Title: Development of Chitosan Particles Loaded with siRNA for Cystatin C to Control Intracellular Drug-Resistant Mycobacterium tuberculosis
    Authors: Pires, D., Mandal, M., Matos, A.I., Florindo, H.F., Anes, E.
    Year: 2023
    Citations: 6

Mohammad Hossein Boskabady | Pharmacology | Best Researcher Award

Posted on by ScienceFather

Dr. Mohammad Hossein Boskabady | Pharmacology | Best Researcher Award

Professor of Clinical Physiology, Mashhad University of Medical Sciences, Iran

Dr. Mohammad Hossein Boskabady is a distinguished researcher in the field of Pharmacology, renowned for his innovative contributions and groundbreaking research. With a strong background in pharmacological sciences, Dr. Boskabady’s work focuses on exploring the therapeutic potentials and mechanisms of various compounds. His extensive research has significantly advanced the understanding of drug actions and interactions, earning him recognition as a leading figure in pharmacological research. Dr. Boskabady’s commitment to scientific excellence and his impactful discoveries make him a deserving candidate for the Best Researcher Award.

Profile

Education 

Dr. Mohammad Hossein Boskabady’s academic journey began with his primary education in Boskabad, Khorasan, followed by high school in Gonabad, Khorasan, Iran. He earned his M.D. from Mashhad University of Medical Sciences. Dr. Boskabady furthered his studies as a postgraduate student in Physiology at University College London before completing his Ph.D. in Medicine at Charing Cross and Westminster Medical School, where he focused his thesis on the responsiveness of human bronchi to pharmacological agonists and antagonists. With a strong commitment to advancing pharmacological research, Dr. Boskabady aims to continue his research and lecturing at the university level, contributing to the field through innovative studies and academic excellence.

Employment

Dr. Mohammad Hossein Boskabady’s professional career began as a Doctor in the Emergency and Casualty Department at Imam Reza Hospital in Mashhad, Iran. Concurrently, he served as a Lecturer in Clinical Physiology at Ghaem Medical Centre, Mashhad University of Medical Sciences. Over the years, Dr. Boskabady advanced through academic ranks, holding positions as Assistant Professor, Associate Professor, and ultimately Professor in Clinical Physiology at the same institution. His extensive experience in both clinical practice and academic teaching underscores his significant contributions to the field of pharmacology and clinical physiology.

Awards

Dr. Mohammad Hossein Boskabady has been recognized for his outstanding contributions to research in Basic Medical Sciences with numerous prestigious awards. From 2000 to 2005, he won First Prizes at the Mashhad University of Medical Sciences Festival every year, and also received Second Prizes at the Razi National Festival in 2002 and 2006. He was honored as a Selected Researcher in Basic Medical Sciences for Khorasan Province in 2007 and 2008. Dr. Boskabady continued to excel, securing First Prizes at the Mashhad University of Medical Sciences Festival from 2009 to 2011, and was awarded Best Researcher at the same festival in 2012, 2013, 2016, and 2019. In 2021, he was recognized as a Selected Researcher at the School of Medicine, Mashhad University of Medical Sciences. Additionally, in November 2017, he was distinguished as a 1% world scientist by Essential Science Indicators (ESI), highlighting his global impact in the field

Official Posts

Dr. Mohammad Hossein Boskabady has held several significant roles throughout his career, reflecting his dedication and leadership in the field of medical sciences. From October 1994 to December 1996, he served as Consultant to the Vice Chancellor for Research at Mashhad University of Medical Sciences. He was a member of the Occupational Health Committee in Khorasan Province from November 1995 to October 1998 and also held the position of Director of International Affairs at Mashhad University of Medical Sciences from October 1996 to April 1999. Additionally, Dr. Boskabady was a member of the Scholarship Council from October 1997 to April 1999. He led the Physiology Department as Head from February 2000 to April 2002. Dr. Boskabady has been a member of the Editorial Board of the Journal of Basic Medical Sciences since October 1995 and has been involved with the Examination Board in Physiology for the Ministry of Health and Medical Education since August 2000. His other roles include serving on various research committees and councils at Mashhad University of Medical Sciences and acting as Secretary General for the 18th Congress of Iranian Physiology and Pharmacology in 2007. Since August 2011, he has been the Director of the Applied Biomedical Research Center at Mashhad University of Medical Sciences, and he has also served as Research Deputy for the School of Medicine from August 2011 to December 2013.

Publication Top Notes
  • Boskabady, M. H., & Snashall, P. D. (1992). Enhanced muscarinic receptor blockade with atropine in the asthmatic tracheobronchial tree: Evidence for increased drug delivery in asthma. American Review of Respiratory Disease, 145(5), 756-761. DOI: 10.1164/ajrccm/145.5.756.
  • Boskabady, M. H., & Snashall, P. D. (1996). Short term variation of atropine blockade in the tracheobronchial tree of asthmatic subjects. Medical Journal of the Islamic Republic of Iran, 10(3), 183-189. DOI: 10.17102/mjiri.1996.0108.
  • Boskabady, M. H., & Snashall, P. D. (1997). Enhanced histamine H1 receptor blockade with chlorpheniramine in the asthmatic tracheobronchial tree: Further evidence for increased drug delivery in asthma. Medical Journal of the Islamic Republic of Iran, 11(2), 115-122. DOI: 10.17102/mjiri.1997.0063.
  • Boskabady, M. H., & Shhabi, M. (1997). Bronchodilatory and anticholinergic effects of Nigella sativa on isolated guinea pig tracheal chains. Iranian Journal of Medical Sciences, 22(4), 127-133. DOI: 10.30476/ijms.1997.0549.
  • Boskabady, M. H., Rakhshandah, H., & Moetamedshariati, V. (1998). Bronchodilatory and anticholinergic effects of Carum copticum on isolated guinea pig tracheal chains. Medical Journal of the Islamic Republic of Iran, 11(5), 329-334. DOI: 10.17102/mjiri.1998.0134.
  • Boskabady, M. H., & Harati, M. (1998). Increased histamine H1 receptor blockade by chlorpheniramine in tracheal chains of asthmatic guinea-pigs. Medical Journal of the Islamic Republic of Iran, 12(2), 265-271. DOI: 10.17102/mjiri.1998.0089.
  • Boskabady, M. H., & Talebi, M. (1999). Bronchodilatory and anticholinergic effects of Carum carvi on isolated guinea pig tracheal chains. Medical Journal of the Islamic Republic of Iran, 12(3), 345-351. DOI: 10.17102/mjiri.1999.0154.
  • Boskabady, M. H., & Adel-Kardan, S. (1999). Increased muscarinic receptor blockade by atropine in tracheal chains of ovalbumin-sensitized guinea-pigs. Pharmacology, 58(6), 300-308. DOI: 10.1159/000029652.
  • Boskabady, M. H., & Shikhi, J. (2000). Inhibitory effect of Carum copticum on histamine (H1) receptors of isolated guinea pig tracheal chains. Journal of Ethnopharmacology, 69(2), 217-227. DOI: 10.1016/S0378-8741(99)00244-3.
  • Boskabady, M. H., & Simaei, N. (1999). Prevalence of asthma among young adults (high school students) in the city of Mashhad (north east of Iran). Iranian Journal of Medical Sciences, 24(1), 48-52. DOI: 10.30476/ijms.1999.0442.
  • Boskabady, M. H., & Snashall, P. D. (2000). Bronchial responsiveness to beta-adrenergic stimulation and enhanced beta blockade in asthma. Respirology, 5(2), 111-118. DOI: 10.1046/j.1440-1843.2000.00243.x.
  • Boskabady, M. H., & Moemeni, A. (2000). Stimulatory effect of Carum copticum on beta2 adrenoceptors of isolated guinea pig tracheal chains. Medical Journal of the Islamic Republic of Iran, 13(3), 273-278. DOI: 10.17102/mjiri.2000.0192.
  • Boskabady, M. H., Karbandy, S., & Abedinzadah, A. (2000). The effects of arterial O2 saturation and heart rate on blood pressure. Medical Journal of the Islamic Republic of Iran, 14(2), 37-41. DOI: 10.17102/mjiri.2000.0200.
  • Boskabady, M. H., & Karimian, M. (2000). Prevalence of asthma among guidance school students (aged 11-16 years) in the city of Mashhad (north east of Iran). Archives of Iranian Medicine, 3(3), 165-169. DOI: 10.30476/aim.2000.0109.
  • Boskabady, M. H., & Hosaini, M. (2000). Effect of patient education and regular PEF measurement on self-management of asthma. Iranian Journal of Allergy, Asthma, and Immunology, 1(2), 159-164. DOI: 10.30476/ijaai.2000.0111.
  • Boskabady, M. H., & Ramazani, M. (2001). Relaxant effect of Pimpinella anisum on isolated guinea pig tracheal chains and its possible mechanism(s). Journal of Ethnopharmacology, 74(1), 83-88. DOI: 10.1016/S0378-8741(00)00382-5.
  • Boskabady, M. H., Keshmiri, M., Banihashemi, B., & Anvary, K. H. (2002). Lung function values in healthy non-smoking urban adults in Iran. Respiration, 69(4), 320-326. DOI: 10.1159/000065155.
  • Boskabady, M. H., & Klahdoz, G. H. (2002). Prevalence of asthma symptoms among the adult population in the city of Mashhad (north-east of Iran). Respirology, 7(3), 267-272. DOI: 10.1046/j.1440-1843.2002.00413.x.
  • Boskabady, M. H., & Shirmohammadi, B. (2002). Effect of Nigella sativa on isolated guinea pig trachea. Archives of Iranian Medicine, 5(2), 103-107. DOI: 10.30476/aim.2002.0145.
  • Boskabady, M. H., & Shiravi, N. (2002). Inhibitory effect of Nigella sativa on histamine (H1) receptors of isolated guinea pig tracheal chains. Pharmaceutical Biology, 40(8), 596-602. DOI: 10.1076/1388-0209(200208)4008-0005.